Literature DB >> 30138692

Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice.

Jia Zhan1, Chloe J Jordan2, Guo-Hua Bi2, Xiang-Hu He1, Eliot L Gardner2, Yan-Lin Wang3, Zheng-Xiong Xi4.   

Abstract

Despite extensive research, the neurobiological risk factors that convey vulnerability to opioid abuse are still unknown. Recent studies suggest that the dopamine D3 receptor (D3R) is involved in opioid self-administration, but it remains unclear whether altered D3R availability is a risk factor for the development of opioid abuse and addiction. Here we used dopamine D3 receptor-knockout (D3-KO) mice to investigate the role of this receptor in the different phases of opioid addiction. D3-KO mice learned to self-administer heroin faster and took more heroin than wild-type mice during acquisition and maintenance of self-administration. D3R-KO mice also displayed higher motivation to work to obtain heroin reward during self-administration under progressive-ratio reinforcement, as well as elevated heroin-seeking during extinction and reinstatement testing. In addition, deletion of the D3R induced higher baseline levels of extracellular dopamine (DA) in the nucleus accumbens (NAc), higher basal levels of locomotion, and reduced NAc DA and locomotor responses to lower doses of heroin. These findings suggest that the D3R is critically involved in regulatory processes that normally limit opioid intake via DA-related mechanisms. Deletion of D3R augments opioid-taking and opioid-seeking behaviors. Therefore, low D3R availability in the brain may represent a risk factor for the development of opioid abuse and addiction. Published by Elsevier Ltd.

Entities:  

Keywords:  Addiction; D3 receptors; Dopamine; Heroin; Reinstatement; Reward; Self-administration

Mesh:

Substances:

Year:  2018        PMID: 30138692      PMCID: PMC6561496          DOI: 10.1016/j.neuropharm.2018.08.016

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  51 in total

1.  Vertical shifts in self-administration dose-response functions predict a drug-vulnerable phenotype predisposed to addiction.

Authors:  P V Piazza; V Deroche-Gamonent; F Rouge-Pont; M Le Moal
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

Review 2.  Dopamine receptor partial agonists could address the duality of cocaine craving.

Authors:  A R Childress; C P O'Brien
Journal:  Trends Pharmacol Sci       Date:  2000-01       Impact factor: 14.819

3.  Food intake, water intake, and drinking spout side preference of 28 mouse strains.

Authors:  Alexander A Bachmanov; Danielle R Reed; Gary K Beauchamp; Michael G Tordoff
Journal:  Behav Genet       Date:  2002-11       Impact factor: 2.805

4.  Dopamine D3 receptors expressed by all mesencephalic dopamine neurons.

Authors:  J Diaz; C Pilon; B Le Foll; C Gros; A Triller; J C Schwartz; P Sokoloff
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

5.  Characterization of dopamine receptor subtypes involved in experimentally induced gastric and duodenal ulcers in rats.

Authors:  J K Desai; R K Goyal; N S Parmar
Journal:  J Pharm Pharmacol       Date:  1999-02       Impact factor: 3.765

6.  Drug-induced reinstatement to heroin and cocaine seeking: a rodent model of relapse in polydrug use.

Authors:  F Leri; J Stewart
Journal:  Exp Clin Psychopharmacol       Date:  2001-08       Impact factor: 3.157

7.  Increased lever pressing for amphetamine after pimozide in rats: implications for a dopamine theory of reward.

Authors:  R A Yokel; R A Wise
Journal:  Science       Date:  1975-02-14       Impact factor: 47.728

8.  Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion.

Authors:  Minoru Narita; Keisuke Mizuo; Hirokazu Mizoguchi; Mamoru Sakata; Michiko Narita; Leon F Tseng; Tsutomu Suzuki
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

9.  Role of DRD3 in morphine-induced conditioned place preference using drd3-knockout mice.

Authors:  Henriette Francès; Bernard Le Foll; Jorge Diaz; Maria Smirnova; Pierre Sokoloff
Journal:  Neuroreport       Date:  2004-10-05       Impact factor: 1.837

10.  Individual differences in cocaine- and amphetamine-induced activation of male Sprague-Dawley rats: contribution of the dopamine transporter.

Authors:  Sophia K Briegleb; Joshua M Gulley; Brian R Hoover; Nancy R Zahniser
Journal:  Neuropsychopharmacology       Date:  2004-12       Impact factor: 7.853

View more
  10 in total

1.  The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents.

Authors:  Chloe J Jordan; Bree Humburg; Myra Rice; Guo-Hua Bi; Zhi-Bing You; Anver Basha Shaik; Jianjing Cao; Alessandro Bonifazi; Alexandra Gadiano; Rana Rais; Barbara Slusher; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-08       Impact factor: 5.250

2.  Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects.

Authors:  Zhi-Bing You; Guo-Hua Bi; Ewa Galaj; Vivek Kumar; Jianjing Cao; Alexandra Gadiano; Rana Rais; Barbara S Slusher; Eliot L Gardner; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  Neuropsychopharmacology       Date:  2018-11-27       Impact factor: 7.853

Review 3.  Aerobic exercise as a promising nonpharmacological therapy for the treatment of substance use disorders.

Authors:  Gigliola Marrero-Cristobal; Ursula Gelpi-Dominguez; Roberto Morales-Silva; John Alvarado-Torres; Joshua Perez-Torres; Yobet Perez-Perez; Marian Sepulveda-Orengo
Journal:  J Neurosci Res       Date:  2021-12-01       Impact factor: 4.433

Review 4.  Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel.

Authors:  Andrea Fagiolini; José Ángel Alcalá; Thomas Aubel; Wojciech Bienkiewicz; Mats Magnus Knut Bogren; Joaquim Gago; Giancarlo Cerveri; Michael Colla; Francisco Collazos Sanchez; Alessandro Cuomo; Frieling Helge; Eduardo Iacoponi; Per-Axel Karlsson; Pradeep Peddu; Mauro Pettorruso; Henrique Jorge Ramos Pereira; Johan Sahlsten Schölin; Ingo Bernd Vernaleken
Journal:  Ann Gen Psychiatry       Date:  2020-09-26       Impact factor: 3.455

5.  Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats.

Authors:  Jun-Tao Gao; Chloe J Jordan; Guo-Hua Bi; Yi He; Hong-Ju Yang; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Neuropsychopharmacology       Date:  2018-10-03       Impact factor: 7.853

Review 6.  Identification of the Risk Genes Associated With Vulnerability to Addiction: Major Findings From Transgenic Animals.

Authors:  Chloe J Jordan; Zheng-Xiong Xi
Journal:  Front Neurosci       Date:  2022-01-12       Impact factor: 4.677

7.  Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor µ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms?

Authors:  Marjorie C Gondré-Lewis; Igor Elman; Tanya Alim; Edwin Chapman; Beverlyn Settles-Reaves; Carine Galvao; Mark S Gold; David Baron; Shan Kazmi; Eliot Gardner; Ashim Gupta; Catherine Dennen; Kenneth Blum
Journal:  Biomedicines       Date:  2022-04-07

8.  (±)VK4-40, a novel dopamine D3 receptor partial agonist, attenuates cocaine reward and relapse in rodents.

Authors:  Chloe J Jordan; Yi He; Guo-Hua Bi; Zhi-Bing You; Jianjing Cao; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  Br J Pharmacol       Date:  2020-09-17       Impact factor: 9.473

Review 9.  Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges.

Authors:  Ewa Galaj; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neurosci Biobehav Rev       Date:  2020-05-03       Impact factor: 8.989

10.  High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial.

Authors:  Mark Moran; Kenneth Blum; Jessica Valdez Ponce; Lisa Lott; Marjorie C Gondré-Lewis; Sampada Badgaiyan; Raymond Brewer; B William Downs; Philip Fynman; Alexander Weingarten; Jean Lud Cadet; David E Smith; David Baron; Panayotis K Thanos; Edward J Modestino; Rajendra D Badgaiyan; Igor Elman; Mark S Gold
Journal:  Mol Neurobiol       Date:  2021-03-08       Impact factor: 5.590

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.